|
US6921762B2
(en)
|
2001-11-16 |
2005-07-26 |
Amgen Inc. |
Substituted indolizine-like compounds and methods of use
|
|
WO2010021381A1
(ja)
|
2008-08-22 |
2010-02-25 |
武田薬品工業株式会社 |
縮合複素環誘導体およびその用途
|
|
EA023788B1
(ru)
|
2010-05-07 |
2016-07-29 |
ГЛЭКСОСМИТКЛАЙН ЭлЭлСи |
Производные индола и фармацевтические композиции на их основе
|
|
JP5864546B2
(ja)
|
2010-05-07 |
2016-02-17 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ |
インダゾール
|
|
US9175331B2
(en)
|
2010-09-10 |
2015-11-03 |
Epizyme, Inc. |
Inhibitors of human EZH2, and methods of use thereof
|
|
US20130310379A1
(en)
|
2010-11-19 |
2013-11-21 |
Constellation Pharmaceuticals |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
|
EP2646455A4
(en)
|
2010-12-03 |
2014-04-02 |
Epizyme Inc |
Modulators of histone methyltransferase, and methods of use thereof
|
|
WO2012118812A2
(en)
|
2011-02-28 |
2012-09-07 |
Epizyme, Inc. |
Substituted 6,5-fused bicyclic heteroaryl compounds
|
|
JO3363B1
(ar)
|
2011-04-13 |
2019-03-13 |
Epizyme Inc |
مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
|
|
TW201733984A
(zh)
|
2011-04-13 |
2017-10-01 |
雅酶股份有限公司 |
經取代之苯化合物
|
|
KR20140033377A
(ko)
|
2011-05-10 |
2014-03-18 |
길리애드 사이언시즈, 인코포레이티드 |
나트륨 채널 조절제로서의 융합된 헤테로시클릭 화합물
|
|
CA2850570A1
(en)
|
2011-09-30 |
2013-04-04 |
Glaxosmithkline Llc |
Methods of treating cancer
|
|
CA2853501A1
(en)
|
2011-10-27 |
2013-05-02 |
Memorial Sloan-Kettering Cancer Center |
Methyltransferase inhibitors for treating cancer
|
|
US9051269B2
(en)
|
2011-11-18 |
2015-06-09 |
Constellation Pharmaceuticals, Inc. |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
|
EP2780014A4
(en)
|
2011-11-18 |
2015-07-01 |
Constellation Pharmaceuticals Inc |
MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
|
|
JP5989805B2
(ja)
|
2012-02-10 |
2016-09-07 |
コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
メチル基変更酵素の調節物質、組成物及びその使用
|
|
SG10201608579UA
(en)
|
2012-04-13 |
2016-12-29 |
Epizyme Inc |
Combination therapy for treating cancer
|
|
US9562041B2
(en)
|
2012-05-16 |
2017-02-07 |
Glaxosmithkline Llc |
Enhancer of zeste homolog 2 inhibitors
|
|
US9105490B2
(en)
|
2012-09-27 |
2015-08-11 |
Taiwan Semiconductor Manufacturing Company, Ltd. |
Contact structure of semiconductor device
|
|
CA2884848C
(en)
|
2012-09-28 |
2017-08-22 |
Pfizer Inc. |
Benzamide and heterobenzamide compounds
|
|
CA2887243C
(en)
|
2012-10-15 |
2024-04-09 |
Epizyme, Inc. |
Methods of treating cancer
|
|
PE20150887A1
(es)
|
2012-10-15 |
2015-06-04 |
Epizyme Inc |
Compuestos de benceno sustituidos
|
|
KR20150095779A
(ko)
|
2012-12-13 |
2015-08-21 |
글락소스미스클라인 엘엘씨 |
제스트 인핸서 상동체 2 억제제
|
|
UA111305C2
(uk)
|
2012-12-21 |
2016-04-11 |
Пфайзер Інк. |
Конденсовані лактами арилу та гетероарилу
|
|
CA2894222A1
(en)
|
2012-12-21 |
2014-06-26 |
Epizyme, Inc. |
1,4-pyridone bicyclic heteroaryl compounds
|
|
WO2014100646A1
(en)
|
2012-12-21 |
2014-06-26 |
Epizyme, Inc. |
1,4-pyridone compounds
|
|
MA38341B1
(fr)
|
2013-02-11 |
2018-11-30 |
Constellation Pharmaceuticals Inc |
Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
|
|
CA2903572A1
(en)
|
2013-03-15 |
2014-10-23 |
Epizyme, Inc. |
Substituted benzene compounds
|
|
US9045477B2
(en)
|
2013-03-15 |
2015-06-02 |
Epizyme, Inc. |
Substituted 6,5-fused bicyclic heteroaryl compounds
|
|
US9745305B2
(en)
|
2013-03-15 |
2017-08-29 |
Constellation Pharmaceuticals, Inc. |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
|
US9243001B2
(en)
|
2013-03-15 |
2016-01-26 |
Epizyme, Inc. |
Substituted benzene compounds
|
|
US9776996B2
(en)
|
2013-03-15 |
2017-10-03 |
Epizyme, Inc. |
Substituted 6,5-fused bicyclic heteroaryl compounds
|
|
WO2014177982A1
(en)
|
2013-04-30 |
2014-11-06 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Enhancer of zeste homolog 2 inhibitors
|
|
EP3004096A1
(en)
|
2013-06-06 |
2016-04-13 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Enhancer of zeste homolog 2 inhibitors
|
|
AU2014288839B2
(en)
|
2013-07-10 |
2017-02-02 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Enhancer of Zeste Homolog 2 inhibitors
|
|
EP3022195A2
(en)
|
2013-07-19 |
2016-05-25 |
Epizyme, Inc. |
Substituted 6,5-fused bicyclic heteroaryl compounds
|
|
WO2015010049A1
(en)
|
2013-07-19 |
2015-01-22 |
Epizyme, Inc. |
Substituted benzene compounds
|
|
US9969716B2
(en)
|
2013-08-15 |
2018-05-15 |
Constellation Pharmaceuticals, Inc. |
Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
|
|
US9738630B2
(en)
|
2013-11-19 |
2017-08-22 |
Bristol-Myers Squibb Company |
Inhibitors of lysine methyl transferase
|
|
US9822103B2
(en)
|
2013-11-22 |
2017-11-21 |
Bristol-Myers Squibb Company |
Inhibitors of lysine methyl transferase
|
|
US20160361309A1
(en)
|
2014-02-26 |
2016-12-15 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Methods of treating cancer patients responding to ezh2 inhibitor gsk126
|
|
EP3114125A1
(en)
|
2014-03-07 |
2017-01-11 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Enhancer of zeste homolog 2 inhibitors
|
|
LT3121175T
(lt)
|
2014-03-17 |
2020-03-10 |
Daiichi Sankyo Company, Limited |
1,3-benzodioksazolo dariniai, kaip ezh1 ir (arba) ezh2 inhibitoriai
|
|
TN2016000529A1
(en)
|
2014-06-17 |
2018-04-04 |
Pfizer |
Substituted dihydroisoquinolinone compounds
|
|
WO2015193768A1
(en)
|
2014-06-17 |
2015-12-23 |
Pfizer Inc. |
Aryl fused lactams as ezh2 modulators
|
|
BR112017008840A2
(pt)
|
2014-10-28 |
2017-12-19 |
Glaxosmithkline Ip No 2 Ltd |
intensificador de inibidores do homólogo 2 de zeste
|
|
WO2016073956A1
(en)
|
2014-11-06 |
2016-05-12 |
Dana-Farber Cancer Institute, Inc. |
Ezh2 inhibitors and uses thereof
|
|
US20190000860A1
(en)
|
2014-11-06 |
2019-01-03 |
Dana-Farber Cancer Institute, Inc. |
Use of compositions modulating chromatin structure for graft versus host disease (gvhd)
|
|
AR102767A1
(es)
|
2014-12-05 |
2017-03-22 |
Lilly Co Eli |
Inhibidores de ezh2
|
|
WO2016102493A1
(en)
|
2014-12-22 |
2016-06-30 |
Bayer Pharma Aktiengesellschaft |
Imidazopyridine ezh2 inhibitors
|
|
UY36462A
(es)
|
2014-12-23 |
2016-07-29 |
Novartis Ag |
Compuestos de triazolopirimidina y usos de los mismos
|
|
IL236420A
(en)
|
2014-12-23 |
2016-06-30 |
Ron Schneider |
Methods and systems for producing an enlarged 3D image
|
|
WO2016123387A1
(en)
|
2015-01-30 |
2016-08-04 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
WO2016130396A1
(en)
|
2015-02-13 |
2016-08-18 |
Constellation Pharmaceuticals, Inc. |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
|
TW201718598A
(zh)
|
2015-08-27 |
2017-06-01 |
美國禮來大藥廠 |
Ｅｚｈ２抑制劑
|
|
RS59763B1
(sr)
|
2015-11-19 |
2020-02-28 |
Jiangsu Hengrui Medicine Co |
Derivati benzofurana, postupci njihove pripreme i njihova upotreba u medicini
|
|
EP3386513A2
(en)
|
2015-12-07 |
2018-10-17 |
Epizyme Inc |
Inhibitors of ezh2 and methods of use thereof
|
|
WO2017174023A1
(zh)
|
2016-04-08 |
2017-10-12 |
南京明德新药研发股份有限公司 |
作为ezh2抑制剂的联苯化合物
|
|
JP7493304B2
(ja)
|
2016-04-22 |
2024-05-31 |
ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド |
Ｅｚｈ２インヒビターおよびそれらの使用
|
|
KR20190003699A
(ko)
|
2016-05-05 |
2019-01-09 |
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 |
제스트 인핸서 상동체 2 억제제
|
|
US9957274B2
(en)
|
2016-05-06 |
2018-05-01 |
Abbvie Inc. |
Indane inhibitors of EED and methods of their use
|
|
WO2017210395A1
(en)
|
2016-06-01 |
2017-12-07 |
Epizyme, Inc. |
Use of ezh2 inhibitors for treating cancer
|
|
EP3471830A4
(en)
|
2016-06-17 |
2020-02-26 |
Epizyme Inc |
EZH2 INHIBITORS TO TREAT CANCER
|
|
ES2975263T3
(es)
|
2016-06-20 |
2024-07-04 |
Novartis Ag |
Formas cristalinas de un compuesto triazolopirimidínico
|
|
EP3472166A1
(en)
*
|
2016-06-20 |
2019-04-24 |
Novartis AG |
Imidazopyrimidine compounds useful for the treatment of cancer
|
|
WO2017221092A1
(en)
*
|
2016-06-20 |
2017-12-28 |
Novartis Ag |
Triazolopyridine compounds and uses thereof
|
|
US10266542B2
(en)
|
2017-03-15 |
2019-04-23 |
Mirati Therapeutics, Inc. |
EZH2 inhibitors
|
|
WO2019062435A1
(zh)
|
2017-09-28 |
2019-04-04 |
中国科学院上海药物研究所 |
三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
|
|
CN109942556A
(zh)
|
2017-12-21 |
2019-06-28 |
上海青煜医药科技有限公司 |
嘧啶酮化合物及其应用
|
|
MX2020007974A
(es)
|
2018-01-31 |
2020-09-07 |
Mirati Therapeutics Inc |
Inhibidores de complejo represivo polycomb 2 (prc2).
|
|
CN110156787B
(zh)
|
2018-02-13 |
2021-11-02 |
中国科学院上海药物研究所 |
一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
|
|
CN110563722A
(zh)
|
2018-06-06 |
2019-12-13 |
上海青煜医药科技有限公司 |
吡啶或哒嗪并环化合物及其应用
|
|
US12421228B2
(en)
|
2019-04-22 |
2025-09-23 |
Mirati Therapeutics, Inc. |
Naphthyridine derivatives as PRC2 inhibitors
|
|
EP3980422A1
(en)
|
2019-06-05 |
2022-04-13 |
Mirati Therapeutics, Inc. |
Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer
|